Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | 17-AAG | 0.0016596 | uM | 7 | 156.25 | 33.46 | 66.00 | 100.50 | 0.6567 | 0.5344 |
| SK-BR-3 | Lapatinib | 0.0033113 | uM | 7 | 156.25 | 33.46 | 106.50 | 100.50 | 1.0597 | 1.0744 |
| SK-BR-3 | Erlotinib | 0.01 | uM | 7 | 156.25 | 33.46 | 133.00 | 100.50 | 1.3234 | 1.3863 |
| SK-BR-3 | 0 | uM | 7 | 156.25 | 33.46 | 90.00 | 100.50 | 0.8955 | 0.8656 | |
| SK-BR-3 | Erlotinib | 3.1623 | uM | 7 | 156.25 | 33.46 | 89.00 | 100.50 | 0.8856 | 0.8526 |
| SK-BR-3 | Lapatinib | 0.0016596 | uM | 7 | 156.25 | 33.46 | 108.00 | 100.50 | 1.0746 | 1.0928 |
| SK-BR-3 | Linsitinib | 1 | uM | 7 | 156.25 | 33.46 | 132.00 | 100.50 | 1.3134 | 1.3749 |
| SK-BR-3 | Lapatinib | 3.1623 | uM | 7 | 156.25 | 33.46 | 60.00 | 100.50 | 0.5970 | 0.4450 |
| SK-BR-3 | Linsitinib | 0.0033113 | uM | 7 | 156.25 | 33.46 | 85.00 | 100.50 | 0.8458 | 0.7996 |
| SK-BR-3 | 17-AAG | 0.31623 | uM | 7 | 156.25 | 33.46 | 60.00 | 100.50 | 0.5970 | 0.4450 |
| SK-BR-3 | 17-AAG | 0.01 | uM | 7 | 156.25 | 33.46 | 71.00 | 100.50 | 0.7065 | 0.6067 |
| SK-BR-3 | Lapatinib | 1 | uM | 7 | 156.25 | 33.46 | 90.00 | 100.50 | 0.8955 | 0.8656 |
| SK-BR-3 | Erlotinib | 0.0033113 | uM | 7 | 156.25 | 33.46 | 84.00 | 100.50 | 0.8358 | 0.7863 |
| SK-BR-3 | Erlotinib | 0.31623 | uM | 7 | 156.25 | 33.46 | 147.00 | 100.50 | 1.4627 | 1.5416 |
| SK-BR-3 | Lapatinib | 0.31623 | uM | 7 | 156.25 | 33.46 | 88.00 | 100.50 | 0.8756 | 0.8394 |
| SK-BR-3 | Erlotinib | 10 | uM | 7 | 156.25 | 33.46 | 95.00 | 100.50 | 0.9453 | 0.9303 |
| SK-BR-3 | Erlotinib | 19.9526 | uM | 7 | 156.25 | 33.46 | 227.00 | 100.50 | 2.2587 | 2.3422 |
| SK-BR-3 | 17-AAG | 0.0033113 | uM | 7 | 156.25 | 33.46 | 54.00 | 100.50 | 0.5373 | 0.3521 |
| SK-BR-3 | Lapatinib | 10 | uM | 7 | 156.25 | 33.46 | 72.00 | 100.50 | 0.7164 | 0.6209 |
| SK-BR-3 | 0 | uM | 7 | 156.25 | 33.46 | 99.00 | 100.50 | 0.9851 | 0.9811 | |
| SK-BR-3 | 0 | uM | 7 | 156.25 | 33.46 | 2.00 | 100.50 | 0.0199 | -0.8306 | |
| SK-BR-3 | 0 | uM | 7 | 312.50 | 169.63 | 2.00 | 278.75 | 0.0072 | -0.9980 | |
| SK-BR-3 | 0 | uM | 7 | 312.50 | 169.63 | 336.00 | 278.75 | 1.2054 | 1.5956 | |
| SK-BR-3 | Linsitinib | 0.01 | uM | 7 | 312.50 | 169.63 | 271.00 | 278.75 | 0.9722 | 0.9228 |
| SK-BR-3 | Linsitinib | 0.031623 | uM | 7 | 312.50 | 169.63 | 327.00 | 278.75 | 1.1731 | 1.4991 |